BRAIN Biotech AG · XETR:BNN
BRAIN Biotech — Investor Day (February 2023)
9 slides from BRAIN Biotech's investor day presentation, Feb 27, 2023
Slide 1: BRAIN Biotech AG Capital Markets Day 2023
BRAIN Biotech AG Creating a #BiobasedFuture Capital Markets Day 2023 Zwingenberg, February 27, 2023 Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption. Creating a #
Slide 2: Quarterly Update: 3M Reporting & Guidance Update
Capital Markets Day 2023 Creating a #BiobasedFuture Quarterly Update: 3M Reporting & Guidance Update Michael Schneiders, CFO Creating a #BiobasedFuture © BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0 31
Slide 3: Business Highlights 3M 22/23
Business Highlights 3M 22/23 very dynamic start to the year Strong revenue growth continues Double digit organic growth in both divisions Breatec strong portfolio addition Biocatalysts keeps on delivering WeissBioTech back to growth Cash at EUR 10.8 Million Creating a #BiobasedFuture © B
Slide 4: Financial Highlights 3M FY 2022/23 at a Glance
Financial Highlights 3M FY 2022/23 at a Glance strong growth path continues Organic Organic 3M 3M Growth Growth Q1 Q1 Growth Growth Comment (in € thousand) 2022/23 2021/22 2022/23 2021/22 Revenues 13,694 10,177 34.5% 19.4% 13,694 10,177 34.5% 19.4% Milestones 40K 3M 21/22 BioScience 3,066 2,775 10.5
Slide 5: Cash & Cash Flow
Cash & Cash Flow cash position increased 3M 3M Q1 Q1 Growth Growth (in € thousand) 2022/23 2021/22 2022/23 2021/22 Comment Gross Cash Flow -1,569 -1,573 0.3% -1,569 -1,573 0.3% Operating Cash Flow -2,044 -193 -960.9% -2,044 -193 -960.9% mostly payables/receivables timing Investing Cash Flow 2,371 -1
Slide 6: Long-Term Revenue Growth Trajectory
Long-Term Revenue Growth Trajectory strong growth driven by Biocatalysts, Breatec inclusion * ** *** **** Staying on growth trajectory from last year Growth: strong organic plus Breatec inclusion Both segments are contributing double digit *purchase BioCatalysts Ltd. **divestment Monteil Cosme
Slide 7: Adjusted EBITDA
Adjusted EBITDA burdened by higher costs, weaker product mix & rising expensed investments Group adj. EBITDA improvement lagging due to: • BioScience: rising personnel costs, wage inflation & higher number of employees, lower milestones in quarter • BioIndustrial: absolute rise but adverse mix effec
Slide 8: General Risk Factor Update
General Risk Factor Update ongoing business risk monitoring Summary: BRAIN Group: overall business remains solid. Supply chain still stretched but partially easing. Inflationary pressures remain high Current Situation: Certain supply chain constraints still persist, mostly caused by consequential ef
Slide 9: Our Targets: FY Guidance and Mid-Term Targets
Our Targets FY Guidance and Mid-Term Targets This FY Guidance Mid-Term Targets, Updated (issued 02/23; 4-6 year targets) Quantitative Guidance (excluding Akribion Genomics) Group sales: around EUR 54 to 57 million EUR 100 million group revenues BioScience: high single digit BioProducts: low doub